Perbon Injection (Polynate Calcium)

Key information summary

Efficacy & effects

This medicine reduces toxicity caused by folate metabolism antagonists, alleviating patient burden. Additionally, it helps enhance therapeutic efficacy when used in combination with 5-Fluorouracil (5-FU) for the treatment of advanced colon cancer. In summary, it improves treatment stability through the reduction of toxicity of folate metabolism antagonists and enhances effectiveness when used alongside colon cancer treatment.

Dosage

1. Methotrexate standard therapy: Administer Polinate as a single dose of 6-12mg via intramuscular injection every 6 hours, 4 times a day. 2. Methotrexate-Polinate rescue therapy: Starting 3 hours after discontinuation of methotrexate, administer Polinate as a single dose of 15mg via intravenous injection every 3 hours for 9 doses, followed by intravenous or intramuscular injection every 6 hours for 8 doses. 3. For advanced colon cancer: 5-Fluorouracil (5-F

Precautions

This drug is not suitable for the treatment of pernicious anemia or megaloblastic anemia due to vitamin B12 deficiency. Blood status may improve during the progression of neurological symptoms, but nerve damage may continue. In the case of injection, care should be taken as glass fragments can mix when opening the ampoule, especially when administering to children or the elderly. Patients who are pregnant or breastfeeding should not use this drug, and caution is especially needed when used in conjunction with 5-FU. This drug can cause allergic reactions such as anaphylaxis or hives; therefore, immediate consultation with a medical professional is required if any adverse reactions occur. Pain or transient discomfort at the injection site may occur, and in rare cases, fever or central nervous system symptoms may also occur. When used in combination with 5-FU, side effects such as diarrhea, skin reactions, and mucositis may increase, necessitating regular blood tests and liver function monitoring. This drug should be used under the guidance of a physician experienced in chemotherapy, and the blood drug concentration must be monitored for therapeutic effect and side effect management. In cases of ascites or renal dysfunction, delayed drug excretion may necessitate high-dose intravenous administration. This drug and methotrexate share the same transporter, so if there is resistance to methotrexate, there may also be resistance to this drug. In patients with central nervous system tumors, repeated administration may lead to drug accumulation, reducing anticancer efficacy, hence overdose should be avoided. This drug is not used for the treatment of megaloblastic anemia caused by DNA synthesis inhibitors. This drug does not have an effect on nephrotoxicity caused by methotrexate, hence caution is required in cases of renal dysfunction. It may enhance liver metabolism, potentially lowering the blood concentrations of some anticonvulsants, thus monitoring and dose adjustment are necessary when co-administered. Caution is required as this drug may increase the efficacy and side effects of 5-FU when used together. If pregnant or breastfeeding, safety regarding the fetus or newborn for this drug has not been established, and consultation with a physician before use is essential. Elderly patients are at higher risk for side effects due to decreased physiological function, requiring special attention. This drug should not be administered intrathecally and, due to its calcium content, the intravenous infusion rate should be restricted.

Side effects

Anaphylactic reactions, hives

Alternatives / Same-ingredient medications

• Pervon Injection 15 mg (Polynate Calcium)

  Same ingredient
• 

  Pervon Tablet (Polynate Calcium)

  Same ingredient
• Pervon Injection 30 mg (Polynate Calcium)

  Same ingredient
• Pfizer Like Cobolamin Injection 15 mg (Polynate Calcium)

  Same ingredient

Related searches